Torrent Pharma launches Adalimumab biosimilar in India
New Delhi: Drug firm Torrent Pharmaceuticals has launched in India its biosimilar Adalimumab, used for the treatment of auto immune disorders, under the brand name 'Adfrar'.The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.It, however, did not give any details about the price at which the biosimilar will be available.Adalimumab...
Login or Register to read the full article
New Delhi: Drug firm Torrent Pharmaceuticals has launched in India its biosimilar Adalimumab, used for the treatment of auto immune disorders, under the brand name 'Adfrar'.
The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
It, however, did not give any details about the price at which the biosimilar will be available.
Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis among others, Torrent Pharmaceuticals said.
Autoimmune disorders are growing ailments and monoclonal antibodies (MAb's) are becoming mainstay of treatment, it added.
Biosimilars are biological products that are similar or highly similar to the originator products and have similar level of efficacy and safety.
The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
It, however, did not give any details about the price at which the biosimilar will be available.
Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis among others, Torrent Pharmaceuticals said.
Autoimmune disorders are growing ailments and monoclonal antibodies (MAb's) are becoming mainstay of treatment, it added.
Biosimilars are biological products that are similar or highly similar to the originator products and have similar level of efficacy and safety.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd